Latest stories on LPCN
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine initiates Phase 3 study of LPCN 1154 for postpartum depression
The Fly59 · neutralproduct/pr
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
PR Newswire63 · neutralproduct/pr
Lipocine Launches Phase 3 BLOOM Study for PPD
TipRanks56 · neutralproduct/pr
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine Updates Sales Agreement Fee Structure with A.G.P.
TipRanks50 · neutralgeneral
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire55 · neutralgeneral
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
8-K/A - Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine GAAP EPS of -$0.32, revenue of $190M
Seeking Alpha34 · bearishearnings
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
PR Newswire50 · neutralearnings
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine Appoints Michael J. Grissinger to Board of Directors
PR Newswire50 · neutralgeneral
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine Plans KOL Webinar on Oral PPD Candidate
TipRanks56 · neutralproduct/pr
Lipocine Showcases Phase 3 Data in Postpartum Depression
TipRanks63 · neutralproduct/pr
Lipocine Showcases Phase 3 Data for Postpartum Depression
TipRanks63 · neutralproduct/pr
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
PR Newswire67 · bullishproduct/pr
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
PR Newswire55 · neutralgeneral
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
PR Newswire50 · neutralearnings